Brief: Clarity Pharmaceuticals Posts HY Loss Attributable A$17.2 Million
29/02/2024 04:09
Feb 29 (Reuters) - Clarity Pharmaceuticals Ltd CU6.AX :
* HY LOSS ATTRIBUTABLE A$17.2 MILLION
Source text for Eikon: ID:nASX56NpbH
Further company coverage: CU6.AX
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Clarity Pharmaceuticals
See all newsBrief: Clarity Pharmaceuticals Signs Commercial Manufacturing Agreement
Brief: Clarity Signs A Large-Scale Manufacturing Supply Agreement For Copper-64 With Theragenics
Brief: Clarity Pharmaceuticals Signs A Large-Scale Manufacturing Supply Agreement
Australia's Clarity Pharmaceuticals rises on bagging cancer detection agent supply
Australia's Clarity Pharma surges as US FDA approves trial